

## Asco 2020 - Tigit yields more remissions, mostly in high PD-L1 patients




Jacob Plieth

[Gilead's \\$375m tie-up with Arcus last week](#) put the spotlight back on anti-Tigit antibodies, where Roche's tiragolumab looks to be in the lead. Roche's updated Asco presentation over the weekend of [tiragolumab's Cityscape trial](#) in first-line NSCLC thus generated interest, though perhaps of even greater relevance were the Swiss firm's plans for tiragolumab. When [Cityscape's abstract dropped](#) the efficacy of the Tecentriq monotherapy comparator arm looked low, but at Asco Roche stressed that this concerned 5.9 months' median follow-up; at 10.9 months the remission rate goes up in the tiragolumab combo and monotherapy arms alike, because numerous unconfirmed remissions have by then been confirmed. The efficacy is especially striking in  $\geq 50\%$  PD-L1 expressers, though a 24% response rate for Tecentriq monotherapy in this group still underperforms the 29% seen in the Impower-110 trial. Roche accepted that Tigit blockade offered little hope as monotherapy, but presented mechanistic data suggesting a role for the mechanism as a key element of an anti-PD-(L)1 combo. However, its Tigit combo also lacks efficacy in low PD-L1 expressers, clouding the commercial opportunity. An NSCLC cohort from [tiragolumab's phase I solid tumour trial](#) will feature at an AACR meeting plenary session on June 23.



### CITYSCAPE rPh II: Tiragolumab plus Tecentriq in 1L NSCLC Updated ORR analysis with 10.9 months median follow-up



Follow-up data cut-off: 02 December, 2019; ITT=intention-to-treat; TPS=tumor proportion score

Source: Roche & Asco.

# Tiragolumab: Broad clinical development program

*Further studies to be started over the course of next 12 months*

Phase 1 G030103	Solid tumors	Ongoing	Data from NSCLC cohort at AACR 2020
Phase 1 G041036	R/R Multiple myeloma or NHL	Ongoing	
Phase 2 CITYSCAPE	Non-small cell lung cancer PD-L1 TPS $\geq$ 1%	Ongoing	Data at ASCO 2020
Phase 3 SKYSCRAPER-01	Non-small cell lung cancer PD-L1 TPS > 50%	FPI Q1 '20	
Phase 3 SKYSCRAPER-02	Extensive stage small-cell lung cancer	FPI Q1 '20	
Phase 2 SKYSCRAPER-04	Cervical cancer PD-L1-selected	FPI exp. Q2 '20	
Phase 1b/2 YO39609	MORPHEUS GI cancer	Ongoing	
Phase 1b/2 W039608	MORPHEUS pancreatic cancer	Ongoing	
Phase 1b/2 W039613	MORPHEUS urothelial carcinoma	Ongoing	

Signal-seeking in various tumor types ongoing; four additional phase 3 studies including chemo-free immune doublets to be initiated in 2020

Source: Roche.

[More from Evaluate Vantage](#)

Evaluate HQ  
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas  
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC  
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2021 Evaluate Ltd.